Clinical Trial Detail

NCT ID NCT03093116
Title A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors TP Therapeutics, Inc.
Indications

Advanced Solid Tumor

non-Hodgkin lymphoma

Therapies

Repotrectinib

Age Groups: senior adult

Additional content available in CKB BOOST